...
首页> 外文期刊>Therapeutics and Clinical Risk Management >Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization
【24h】

Resolution of vitreomacular traction following intravitreal ranibizumab in cases of ocular toxoplasmosis with choroidal neovascularization

机译:玻璃体腔内雷珠单抗治疗后眼球弓形体病合并脉络膜新生血管的玻璃体牵引

获取原文

摘要

Purpose: To present the occurrence of the resolution of vitreomacular traction following intravitreal ranibizumab in two patients with inflammatory choroidal neovascular (CNV) membrane with a background of ocular toxoplasmosis. Methods: Interventional case report. Results: A 21-year-old Caucasian woman and a 52-year-old Caucasian man both presented with vitreomacular traction with coexistent classic CNV membrane and a background of ocular toxoplasmosis. They both received an intravitreal injection of ranibizumab in an effort to control the underlying CNV membrane. A resolution of the vitreomacular traction was observed within 1 week of the intravitreal injection in both cases. Conclusion: To the best of our knowledge, this is the first reported case of vitreomacular traction resolution in two patients with ocular toxoplasmosis following ranibizumab administration. Of course, further studies are needed in order to adequately support this association.
机译:目的:介绍玻璃体腔内兰尼单抗治疗后发生眼球弓形体病的两名炎症性脉络膜新生血管(CNV)膜患者发生玻璃体牵引的情况。方法:介入病例报告。结果:21岁的白种女人和52岁的白种男人均表现为玻璃体牵引,并存经典的CNV膜并伴有眼弓形体病。他们俩都接受了雷珠单抗的玻璃体内注射,以控制下面的CNV膜。在两种情况下,玻璃体内注射后1周内均观察到玻璃体牵引力的降低。结论:就我们所知,这是首次接受雷珠单抗治疗后发生的两例眼弓形体病患者玻璃体牵引力下降的病例。当然,需要进一步研究以充分支持这种关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号